Ascentage Pharma Group Internat (AAPG)Healthcare | Biotechnology | Suzhou, China | NasdaqGM
18.73 USD
+1.83
(10.828%)
⇧
(Aug. 27, 2026, 4 p.m.
EDT)
After hours: 18.79 +0.06 (0.320%) ⇧ (Aug. 27, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:15 a.m. EDT
The stock presents a classic biotech dilemma: explosive top-line growth masking a precarious financial foundation. While revenue surged 162% recently and the 29% annual growth rate suggests a promising pipeline, the company is burning cash aggressively, with operating cash flow and free cash flow both deeply negative. This is compounded by a massive debt load relative to equity, creating a fragile balance sheet that limits operational flexibility. The recent price action shows a modest bounce off the lows, moving from the $16 range back toward $19, yet it remains significantly discounted against the $48 mean analyst target. However, this discount reflects the reality that the market is pricing in significant execution risk and dilution potential rather than immediate profitability. With no dividend to provide income and no multi-year price history to confirm a trend reversal, the investment case relies entirely on the successful commercialization of its drug candidates. For now, the uncertainty outweighs the upside, making it a speculative hold rather than a conviction play. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.062877 |
| AutoETS | 0.067218 |
| AutoTheta | 0.068791 |
| AutoARIMA | 0.083054 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.55 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.255 |
| Excess Kurtosis | -0.87 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 370.175 |
| Revenue per Share | 6.912 |
| Market Cap | 1,749,174,912 |
| Forward P/E | -13.90 |
| Beta | 0.67 |
| Profit Margins | -228.54% |
| Website | https://www.ascentage.cn |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.55898285 |
| Address1 | Suzhou Industrial Park |
| Address2 | 68 Xinqing Road |
| All Time High | 48.45 |
| All Time Low | 16.36 |
| Ask | 23.14 |
| Ask Size | 1 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 8,020 |
| Average Daily Volume3 Month | 10,873 |
| Average Volume | 10,873 |
| Average Volume10Days | 8,020 |
| Beta | 0.672 |
| Bid | 18.19 |
| Bid Size | 1 |
| Book Value | 0.88710326 |
| City | Suzhou |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | China |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 18.73 |
| Current Ratio | 1.218 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 18.73 |
| Day Low | 18.26 |
| Debt To Equity | 370.175 |
| Display Name | Ascentage Pharma |
| Earnings Call Timestamp End | 1,787,227,200 |
| Earnings Call Timestamp Start | 1,787,227,200 |
| Earnings Timestamp | 1,787,142,600 |
| Earnings Timestamp End | 1,787,142,600 |
| Earnings Timestamp Start | 1,787,142,600 |
| Ebitda | -1,335,864,064 |
| Ebitda Margins | -2.07873 |
| Enterprise To Ebitda | -1.464 |
| Enterprise To Revenue | 3.044 |
| Enterprise Value | 1,956,168,832 |
| Eps Current Year | -1.44 |
| Eps Forward | -1.3475 |
| Eps Trailing Twelve Months | -2.35 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 18.18648 |
| Fifty Day Average Change | 0.54352 |
| Fifty Day Average Change Percent | 0.029885937 |
| Fifty Two Week Change Percent | -55.898285 |
| Fifty Two Week High | 42.48 |
| Fifty Two Week High Change | -23.75 |
| Fifty Two Week High Change Percent | -0.5590866 |
| Fifty Two Week Low | 16.36 |
| Fifty Two Week Low Change | 2.369999 |
| Fifty Two Week Low Change Percent | 0.14486545 |
| Fifty Two Week Range | 16.36 - 42.48 |
| Financial Currency | CNY |
| First Trade Date Milliseconds | 1,737,729,000,000 |
| Float Shares | 71,538,620 |
| Forward Eps | -1.3475 |
| Forward P E | -13.899815 |
| Free Cashflow | -956,540,352 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 828 |
| Fullday Change | 1.83 |
| Fullday Change Percent | 10.8284 |
| Fullday Price | 18.79 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.9393 |
| Gross Profits | 603,624,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.00035999998 |
| Implied Shares Outstanding | 93,388,942 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor. In addition, it is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China. |
| Market | us_market |
| Market Cap | 1,749,174,912 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_620569787 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -1,468,695,040 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,569,798,329 |
| Number Of Analyst Opinions | 9 |
| Open | 18.42 |
| Operating Cashflow | -1,323,240,960 |
| Operating Margins | -2.48914 |
| Payout Ratio | 0.0 |
| Phone | 86 512 8555 7777 |
| Post Market Change | 0.060001373 |
| Post Market Change Percent | 0.32034904 |
| Post Market Price | 18.79 |
| Post Market Time | 1,787,873,405 |
| Previous Close | 16.9 |
| Price Eps Current Year | -13.006944 |
| Price Hint | 2 |
| Price To Book | 21.113663 |
| Price To Sales Trailing12 Months | 2.7218792 |
| Profit Margins | -2.28543 |
| Quick Ratio | 1.089 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | 1.8299999 |
| Regular Market Change Percent | 10.828402 |
| Regular Market Day High | 18.73 |
| Regular Market Day Low | 18.26 |
| Regular Market Day Range | 18.26 - 18.73 |
| Regular Market Open | 18.42 |
| Regular Market Previous Close | 16.9 |
| Regular Market Price | 18.73 |
| Regular Market Time | 1,787,860,800 |
| Regular Market Volume | 15,518 |
| Return On Assets | -0.28044 |
| Return On Equity | -2.36629 |
| Revenue Growth | 0.293 |
| Revenue Per Share | 6.912 |
| Sand P52 Week Change | 0.1890428 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 93,388,942 |
| Shares Percent Shares Out | 0.0002 |
| Shares Short | 14,177 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 20,246 |
| Short Name | Ascentage Pharma Group Internat |
| Short Percent Of Float | 0.0002 |
| Short Ratio | 2.76 |
| Source Interval | 15 |
| Symbol | AAPG |
| Target High Price | 55.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 47.44444 |
| Target Median Price | 47.0 |
| Total Cash | 1,895,582,976 |
| Total Cash Per Share | 20.314 |
| Total Debt | 2,094,571,008 |
| Total Revenue | 642,635,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.35 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.328215 |
| Two Hundred Day Average Change | -4.598215 |
| Two Hundred Day Average Change Percent | -0.1971096 |
| Type Disp | Equity |
| Volume | 15,518 |
| Website | https://www.ascentage.cn |
| Zip | 215,000 |